---
figid: PMC5515628__coaci-17-309-g002
figlink: /pmc/articles/PMC5515628/figure/F1/
number: F1
caption: 'AD immunopathology and mechanisms of action of targeted therapies. AD immunopathology
  (central picture): damage in the skin barrier promotes the penetration of allergens
  into the skin and facilitate the entrance of microbial products. Antigens are taken
  up by LC and IDEC, initiating the sensitization and T-cell driven immune response.
  In the acute phase, Th2 and Th22 responses are augmented with contribution of Th17.
  The proinflammatory mediators produced in this phase further contribute to the impairment
  of the skin barrier and to the activation of different cell types that enhance the
  skin inflammation. Progression into chronicity involves an increased role of the
  Th1 pathway, but with important contributions of other T-cell subpopulations. Targeted
  therapies (external pictures, counter-clockwise from top left). Mechanism of action
  of nemolizumab (anti-IL-31 receptor antibody); omalizumab (anti-IgE antibody); JAK
  inhibitors; dupilumab (anti-IL-4/IL-13 receptors antibody); PDE4 inhibitors; and
  ustekinumab (anti-IL-12/-23p40 antibody). AD, atopic dermatitis; B, basophil; DC,
  dendritic cell; E, eosinophil. IDEC, inflammatory dendritic epidermal cells; ILC,
  innate lymphoid cell; LC, Langerhans cells; MC, mast cell; PDE, phosphodiesterase;
  Th, T-helper.'
pmcid: PMC5515628
papertitle: Atopic dermatitis phenotypes and the need for personalized medicine.
reftext: Beatriz Cabanillas, et al. Curr Opin Allergy Clin Immunol. 2017 Aug;17(4):309-315.
pmc_ranked_result_index: '174942'
pathway_score: 0.9190658
filename: coaci-17-309-g002.jpg
figtitle: AD immunopathology and mechanisms of action of targeted therapies
year: '2017'
organisms: Homo sapiens
ndex: 65d133a6-df09-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5515628__coaci-17-309-g002.html
  '@type': Dataset
  description: 'AD immunopathology and mechanisms of action of targeted therapies.
    AD immunopathology (central picture): damage in the skin barrier promotes the
    penetration of allergens into the skin and facilitate the entrance of microbial
    products. Antigens are taken up by LC and IDEC, initiating the sensitization and
    T-cell driven immune response. In the acute phase, Th2 and Th22 responses are
    augmented with contribution of Th17. The proinflammatory mediators produced in
    this phase further contribute to the impairment of the skin barrier and to the
    activation of different cell types that enhance the skin inflammation. Progression
    into chronicity involves an increased role of the Th1 pathway, but with important
    contributions of other T-cell subpopulations. Targeted therapies (external pictures,
    counter-clockwise from top left). Mechanism of action of nemolizumab (anti-IL-31
    receptor antibody); omalizumab (anti-IgE antibody); JAK inhibitors; dupilumab
    (anti-IL-4/IL-13 receptors antibody); PDE4 inhibitors; and ustekinumab (anti-IL-12/-23p40
    antibody). AD, atopic dermatitis; B, basophil; DC, dendritic cell; E, eosinophil.
    IDEC, inflammatory dendritic epidermal cells; ILC, innate lymphoid cell; LC, Langerhans
    cells; MC, mast cell; PDE, phosphodiesterase; Th, T-helper.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDE4A
  - PDE4C
  - RPL31
  - IL12A
  - JAK2
  - JAK3
  - PDE4D
  - PDE4B
  - OSMR
  - IL22
  - TYK2
  - IL12B
  - IL31
  - JAK1
  - IL23A
  - IFNA1
  - IL13
  - IL5
  - MFAP1
  - IL4
genes:
- word: PDE4
  symbol: PDE4
  source: bioentities_symbol
  hgnc_symbol: PDE4A
  entrez: '5141'
- word: PDE4
  symbol: PDE4
  source: bioentities_symbol
  hgnc_symbol: PDE4C
  entrez: '5143'
- word: L31
  symbol: L31
  source: hgnc_alias_symbol
  hgnc_symbol: RPL31
  entrez: '6160'
- word: IL12
  symbol: IL12
  source: bioentities_symbol
  hgnc_symbol: IL12A
  entrez: '3592'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: PDE4
  symbol: PDE4
  source: bioentities_symbol
  hgnc_symbol: PDE4D
  entrez: '5144'
- word: PDE4
  symbol: PDE4
  source: bioentities_symbol
  hgnc_symbol: PDE4B
  entrez: '5142'
- word: OSMR
  symbol: OSMR
  source: hgnc_symbol
  hgnc_symbol: OSMR
  entrez: '9180'
- word: IL-22
  symbol: IL22
  source: hgnc_symbol
  hgnc_symbol: IL22
  entrez: '50616'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: IL12
  symbol: IL12
  source: bioentities_symbol
  hgnc_symbol: IL12B
  entrez: '3593'
- word: IL31
  symbol: IL31
  source: hgnc_symbol
  hgnc_symbol: IL31
  entrez: '386653'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: IL23
  symbol: IL-23
  source: hgnc_alias_symbol
  hgnc_symbol: IL23A
  entrez: '51561'
- word: IL-23
  symbol: IL-23
  source: hgnc_alias_symbol
  hgnc_symbol: IL23A
  entrez: '51561'
- word: IFN-
  symbol: IFN
  source: hgnc_alias_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: IL-13
  symbol: IL-13
  source: hgnc_alias_symbol
  hgnc_symbol: IL13
  entrez: '3596'
- word: IL-5
  symbol: IL-5
  source: hgnc_alias_symbol
  hgnc_symbol: IL5
  entrez: '3567'
- word: IL-31
  symbol: IL-31
  source: hgnc_alias_symbol
  hgnc_symbol: IL31
  entrez: '386653'
- word: AMP
  symbol: AMP
  source: hgnc_alias_symbol
  hgnc_symbol: MFAP1
  entrez: '4236'
- word: IL4
  symbol: IL4
  source: hgnc_symbol
  hgnc_symbol: IL4
  entrez: '3565'
chemicals: []
diseases: []
figid_alias: PMC5515628__F1
redirect_from: /figures/PMC5515628__F1
figtype: Figure
---
